Presentation is loading. Please wait.

Presentation is loading. Please wait.

PharmaCog WP5 / E-ADNI. Enrollment and follow-ups Clinical sites Maximum Minimum PATIENTS EXPECTED.

Published byLeslie Bruce Modified over 8 years ago

Similar presentations

Presentation on theme: "PharmaCog WP5 / E-ADNI. Enrollment and follow-ups Clinical sites Maximum Minimum PATIENTS EXPECTED."— Presentation transcript:

1 PharmaCog WP5 / E-ADNI

2 Enrollment and follow-ups Clinical sites Maximum Minimum PATIENTS EXPECTED

3 JournalTitleStatusAuthor Journal of Internal Medicine Clinical and biomarker profiling of prodromal Alzheimer’s disease in IMI Pharmacog’s WP5: a “European ADNI study” SubmittedGalluzzi et al. Human Brain MappingTest-Retest Reliability of the Default Mode Network in a Multicentric fMRI Elderly Study: Effects of Data-Driven Physiological Noise Correction Techniques SubmittedMarchitelli et al Human Brain MappingLongitudinal reproducibility of automatically segmented hippocampal subfields: a multi-site European 3T study on healthy elderly Published in Sept 2015 Marizzoni et al. NeuroImageLongitudinal reproducibility of default-mode network connectivity in healthy elderly participants: a multicentric resting-state fMRI study Published in July 2015 Jovicich et al. NeuroImageMultisite Longitudinal Reliability of Tract-Based Spatial Statistics in Diffusion Tensor Imaging of Healthy Elderly Subjects Published in Nov 2014 Jovicich et al. Drug Discovery Today: Therapeutic Strategies A new paradigm for testing AD drugs – neuroimaging biomarkers as surrogate outcomes homologous in animals and humans Published in Oct 2014 Marizzoni et al. NeuroImageBrain morphometry reproducibility in multi-center 3T MRI studies: A comparison of cross-sectional and longitudinal segmentations Published in Dec 2013 Jovicich et al. Journal of Alzheimer’s Disease Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stagePublished in Aug 2011 Drago et al. Peer-reviewed Publications

4 Baseline CSF Aβ, Aβ/t-tau and Aβ/p-tau distributions to classify PharmaCog MCI patients

5 Cognitive and hippocampal volume changes

6 Series of papers in preparation The IMI PharmaCog WP5/European ADNI study: status and progression of prodromal AD as revealed by a matrix of clinical, neuropsychological, and biological markers Peer-reviewed Publications Introduction Cross-sectional papers Longitudinal papers 22 papers divided into Special issue of peer-reviewed journal

Download ppt "PharmaCog WP5 / E-ADNI. Enrollment and follow-ups Clinical sites Maximum Minimum PATIENTS EXPECTED."

Similar presentations

Corpus Callosum Damage Predicts Disability Progression and Cognitive Dysfunction in Primary-Progressive MS After Five Years.

Corpus Callosum Damage Predicts Disability Progression and Cognitive Dysfunction in Primary-Progressive MS After Five Years.
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing AUSTRALIAN ADNI. July 2010 UPDATE.

The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing AUSTRALIAN ADNI. July 2010 UPDATE.
ADNI PiB Amyloid Imaging Chet Mathis University of Pittsburgh.

ADNI PiB Amyloid Imaging Chet Mathis University of Pittsburgh.
Agenda: - Update on master tracers’ segmentation check - Update validation vs pathology - PMT application submission of “Study on the validation of VSRAD”

Agenda: - Update on master tracers’ segmentation check - Update validation vs pathology - PMT application submission of “Study on the validation of VSRAD”
National Alliance for Medical Image Computing Core 3-1.2 DBP Dartmouth Data NA-MIC National Alliance for Medical Image Computing

National Alliance for Medical Image Computing Core DBP Dartmouth Data NA-MIC National Alliance for Medical Image Computing
FOCUS ON NLM RESOURCES: CLINICALTRIALS.GOV. WHAT IS A CLINICAL STUDY?  Research study using human subjects.  Volunteers may have a certain disease or.

FOCUS ON NLM RESOURCES: CLINICALTRIALS.GOV. WHAT IS A CLINICAL STUDY?  Research study using human subjects.  Volunteers may have a certain disease or.
Disclosures/Conflicts Consulting: GE Healthcare Bayer Abbott Elan/Janssen Synarc Genentech Merck.

Disclosures/Conflicts Consulting: GE Healthcare Bayer Abbott Elan/Janssen Synarc Genentech Merck.
Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April
ADNI 3 Clinical Core Plans

ADNI 3 Clinical Core Plans
Public Health Julie C. Chapman, PsyD Director of Neuroscience War Related Illness & Injury Study Center Veterans Affairs Medical Center, Washington, DC.

Public Health Julie C. Chapman, PsyD Director of Neuroscience War Related Illness & Injury Study Center Veterans Affairs Medical Center, Washington, DC.
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.

Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.

MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.
Brain Changes in 676 ADNI subjects: Summary of 10 Studies using Tensor Based Morphometry & Automated Hippocampal Maps Paul Thompson and the UCLA ADNI.

Brain Changes in 676 ADNI subjects: Summary of 10 Studies using Tensor Based Morphometry & Automated Hippocampal Maps Paul Thompson and the UCLA ADNI.
MNTP Trainee: Georgina Vinyes Junque, Chi Hun Kim Prof. James T. Becker Cyrus Raji, Leonid Teverovskiy, and Robert Tamburo.

MNTP Trainee: Georgina Vinyes Junque, Chi Hun Kim Prof. James T. Becker Cyrus Raji, Leonid Teverovskiy, and Robert Tamburo.
All Hands Meeting 2005 Morphometry BIRN - Overview - Scientific Achievements.

All Hands Meeting 2005 Morphometry BIRN - Overview - Scientific Achievements.
EPAD update José Luis Molinuevo Worldwide-ADNI Update Meeting Friday, July 17, 2015 Washington, D.C.

EPAD update José Luis Molinuevo Worldwide-ADNI Update Meeting Friday, July 17, 2015 Washington, D.C.
How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.

How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.

Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
Alzheimer’s disease Platforms for translational research.

Alzheimer’s disease Platforms for translational research.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.

COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.

Similar presentations

Ads by Google